1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience

MLA

Roberto Ferrara, et al. “1329P Immune Checkpoint Inhibitors in Advanced NSCLC Patients with Poor Performance Status: The Role of Clinical-Pathological Variables and Inflammatory Biomarkers in a Real World Experience.” Annals of Oncology, vol. 31, Sept. 2020, pp. S856–57. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.1643.

APA

Roberto Ferrara, C.M. Della Corte, Floriana Morgillo, Giulia Galli, Francesca Sparano, R. Di Liello, Marina Chiara Garassino, Monica Ganzinelli, Arsela Prelaj, Giuseppe Viscardi, Marta Brambilla, G. Lo Russo, Riccardo Lobefaro, Claudia Proto, Benedetta Trevisan, Diego Signorelli, A. De Toma, Maria Lucia Iacovino, Giacomo Massa, & F. de Braud. (2020). 1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience. Annals of Oncology, 31, S856–S857. https://doi.org/10.1016/j.annonc.2020.08.1643

Chicago

Roberto Ferrara, C.M. Della Corte, Floriana Morgillo, Giulia Galli, Francesca Sparano, R. Di Liello, Marina Chiara Garassino, et al. 2020. “1329P Immune Checkpoint Inhibitors in Advanced NSCLC Patients with Poor Performance Status: The Role of Clinical-Pathological Variables and Inflammatory Biomarkers in a Real World Experience.” Annals of Oncology 31 (September): S856–57. doi:10.1016/j.annonc.2020.08.1643.